Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.

MLA

Kalincik, Tomas, et al. “Comparison of Fingolimod, Dimethyl Fumarate and Teriflunomide for Multiple Sclerosis.” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 90, no. 4, Apr. 2019, pp. 458–68. EBSCOhost, https://doi.org/10.1136/jnnp-2018-319831.

APA

Kalincik, T., Kubala Havrdova, E., Horakova, D., Izquierdo, G., Prat, A., Girard, M., Duquette, P., Grammond, P., Onofrj, M., Lugaresi, A., Ozakbas, S., Kappos, L., Kuhle, J., Terzi, M., Lechner-Scott, J., Boz, C., Grand’Maison, F., Prevost, J., Sola, P., … Butzkueven, H. (2019). Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry, 90(4), 458–468. https://doi.org/10.1136/jnnp-2018-319831

Chicago

Kalincik, Tomas, Eva Kubala Havrdova, Dana Horakova, Guillermo Izquierdo, Alexandre Prat, Marc Girard, Pierre Duquette, et al. 2019. “Comparison of Fingolimod, Dimethyl Fumarate and Teriflunomide for Multiple Sclerosis.” Journal of Neurology, Neurosurgery, and Psychiatry 90 (4): 458–68. doi:10.1136/jnnp-2018-319831.